Dr Reddy's Laboratories Revenue 2012-2025 | RDY
Dr Reddy's Laboratories annual/quarterly revenue history and growth rate from 2012 to 2025. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- Dr Reddy's Laboratories revenue for the quarter ending December 31, 2025 was $0.977B, a 0.9% decline year-over-year.
- Dr Reddy's Laboratories revenue for the twelve months ending December 31, 2025 was $3.937B, a 6.5% increase year-over-year.
- Dr Reddy's Laboratories annual revenue for 2026 was $3.796B, a 0.39% decline from 2025.
- Dr Reddy's Laboratories annual revenue for 2025 was $3.811B, a 13.76% increase from 2024.
- Dr Reddy's Laboratories annual revenue for 2024 was $3.35B, a 11.97% increase from 2023.
|
Dr Reddy's Laboratories Annual Revenue (Millions of US $) |
|
|---|---|
| 2026 | $3,796 |
| 2025 | $3,811 |
| 2024 | $3,350 |
| 2023 | $2,992 |
| 2022 | $2,826 |
| 2021 | $2,594 |
| 2020 | $2,316 |
| 2019 | $2,225 |
| 2018 | $2,181 |
| 2017 | $2,171 |
| 2016 | $2,335 |
| 2015 | $2,378 |
| 2014 | $2,203 |
| 2013 | $2,133 |
| 2012 | $1,901 |
|
Dr Reddy's Laboratories Quarterly Revenue (Millions of US $) |
|
|---|---|
| 2025-12-31 | $977 |
| 2025-09-30 | $1,013 |
| 2025-06-30 | $997 |
| 2025-03-31 | $950 |
| 2024-12-31 | $986 |
| 2024-09-30 | $954 |
| 2024-06-30 | $921 |
| 2024-03-31 | $835 |
| 2023-12-31 | $866 |
| 2023-09-30 | $828 |
| 2023-06-30 | $821 |
| 2023-03-31 | $718 |
| 2022-12-31 | $826 |
| 2022-09-30 | $788 |
| 2022-06-30 | $660 |
| 2022-03-31 | $671 |
| 2021-12-31 | $715 |
| 2021-09-30 | $778 |
| 2021-06-30 | $662 |
| 2021-03-31 | $673 |
| 2020-12-31 | $675 |
| 2020-09-30 | $661 |
| 2020-06-30 | $585 |
| 2020-03-31 | $458 |
| 2019-12-31 | $618 |
| 2019-09-30 | $682 |
| 2019-06-30 | $558 |
| 2019-03-31 | $604 |
| 2018-12-31 | $535 |
| 2018-09-30 | $543 |
| 2018-06-30 | $543 |
| 2018-03-31 | $525 |
| 2017-12-31 | $590 |
| 2017-09-30 | $553 |
| 2017-06-30 | $513 |
| 2017-03-31 | $608 |
| 2016-12-31 | $546 |
| 2016-09-30 | $538 |
| 2016-06-30 | $479 |
| 2016-03-31 | $527 |
| 2015-12-31 | $603 |
| 2015-09-30 | $614 |
| 2015-06-30 | $591 |
| 2015-03-31 | $621 |
| 2014-12-31 | $610 |
| 2014-09-30 | $579 |
| 2014-06-30 | $586 |
| 2014-03-31 | $580 |
| 2013-12-31 | $571 |
| 2013-09-30 | $537 |
| 2013-06-30 | $478 |
| 2013-03-31 | $613 |
| 2012-12-31 | $522 |
| 2012-09-30 | $544 |
| 2012-06-30 | $457 |
| 2012-03-31 | $522 |
| 2011-12-31 | $522 |
| 2011-09-30 | $462 |
| 2011-06-30 | $444 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $11.109B | $3.811B |
| Dr. Reddy's Laboratories Ltd. is an integrated global pharmaceutical company engaged in providing affordable and innovative medicines since 1984. The company markets its products in countries like the U.S., the UK, Germany, India, Russia, Venezuela, Romania and South Africa. Dr. Reddy's operates through three segments: Global Generics comprising unbranded prescription drugs along with over-the-counter drugs. It includes the operations of the company's biologics business. Pharmaceutical Services & Active Ingredients (PSAI) comprising active pharmaceutical ingredients (API) and custom pharmaceutical services. Proprietary Products and Others involving the new chemical entities, the differentiated formulations business and a dermatology specialty business. The company has a strategic partnership with Glaxo to market selected products across emerging markets outside India. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $35.437B | 10.97 |
| BridgeBio Pharma (BBIO) | United States | $14.460B | 0.00 |
| Aspen Pharmacare (APNHY) | South Africa | $3.708B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.918B | 22.33 |
| Bausch Health Cos (BHC) | Canada | $2.086B | 1.50 |
| Taysha Gene Therapies (TSHA) | United States | $1.290B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $0.924B | 7.28 |
| Personalis (PSNL) | United States | $0.630B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.451B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.210B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.052B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |